MarketPulse
C

$CNTA

2 articles found
0 positive
0 negative
2 neutral
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Vertex Pharmaceuticals Outpaces Centessa With Established Revenue and Advanced Pipeline

Vertex Pharmaceuticals outperforms Centessa with profitable cystic fibrosis revenue, successful product launches, and advanced pipeline, offering lower-risk investment profile versus pre-revenue competitor.
VRTXCNTAbiotechclinical trials
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Exits Majority Centessa Stake as Stock Rallies 53%

Commodore Capital exits majority Centessa stake, selling 1.85M shares for $46.86M amid 53% stock rally and company's strategic leadership changes.
CNTAbiotechclinical-stage